Furthermore, Metsera’s IPO opened 42% higher on the Nasdaq Global Select Market, with several financial firms acting as joint bookrunners for the offering. These developments indicate a strong ...

Furthermore, Metsera’s IPO opened 42% higher on the Nasdaq Global Select Market, with several financial firms acting as joint bookrunners for the offering. These developments indicate a strong ...

Last September, another obesity-focused biotech, BioAge, completed an upsized IPO that raised $198 million, after the number of shares on offer was hiked by 40%. Metsera's lead asset is MET-097i ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Structure Therapeutics (GPCR) stock is initiated with a buy rating and a $60 price goal, at Citi due to the potential in its ...